Kelun-Biotech Presents Final Overall Survival Results From OptiTROP-Lung04
Kelun-Biotech said the prespecified final overall survival analysis from its Phase III OptiTROP-Lung04 study was presented at the 2026 ESMO Congress.
Kelun-Biotech said the prespecified final overall survival analysis from its Phase III OptiTROP-Lung04 study was presented at the 2026 ESMO Congress.